Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.7% – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price rose 4.7% during trading on Monday. The company traded as high as $28.15 and last traded at $28.3770. 177,749 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 664,715 shares. The stock had previously closed at $27.11.

Analyst Ratings Changes

Several analysts recently weighed in on MAZE shares. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Citigroup started coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The stock has a market capitalization of $1.59 billion, a PE ratio of -11.32 and a beta of 2.16. The firm has a fifty day moving average price of $26.85 and a two-hundred day moving average price of $27.26.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). Research analysts expect that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the transaction, the chief executive officer directly owned 15,558 shares in the company, valued at approximately $420,377.16. This represents a 68.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Courtney Phillips sold 2,012 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares in the company, valued at approximately $182,252.07. The trade was a 22.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 192,991 shares of company stock valued at $5,152,084 in the last three months. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada grew its stake in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Maze Therapeutics during the second quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics during the fourth quarter worth approximately $145,000. Finally, Persistent Asset Partners Ltd purchased a new position in Maze Therapeutics during the 2nd quarter worth $200,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.